2012
DOI: 10.1055/s-0032-1311529 View full text |Buy / Rent full text
|
|

Abstract: The median survival benefit of 9 months is evident but (probably still) not significant. The more aggressive protocol 2 shows a significant better downstaging effect concerning N- and UICC-stage if R0-resection can be achieved. Insofar dose does matter!

Help me understand this report

Search citation statements

Order By: Relevance
Select...
1
0
1
0

Year Published

2015
2015
2015
2015

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

0
1
0
Order By: Relevance
“…Concerning neoadjuvant chemotherapy, most trials administered three cycles [ 5 8 ]. Recently, Steger et al [ 16 ] compared two different neoadjuvant protocols in a single center retrospective study and concluded that the more aggressive protocol showed a better downstaging effect but survival difference did not reach significance. A two cycle strategy has been evaluated by a French group comparing mitomycin/ ifosfamid/ cisplatin with surgery alone [ 2 ].…”
Section: Discussionmentioning
Create an account to read the remaining citation statements from this report. You will also get access to:
  • Search over 1.2b+ citation statments to see what is being said about any topic in the research literature
  • Advanced Search to find publications that support or contrast your research
  • Citation reports and visualizations to easily see what publications are saying about each other
  • Browser extension to see Smart Citations wherever you read research
  • Dashboards to evaluate and keep track of groups of publications
  • Alerts to stay on top of citations as they happen
  • Automated reference checks to make sure you are citing reliable research in your manuscripts
  • 14 day free preview of our premium features.

Trusted by researchers and organizations around the world

Over 130,000 students researchers, and industry experts at use scite

See what students are saying

rupbmjkragerfmgwileyiopcupepmcmbcthiemesagefrontiersapsiucrarxivemeralduhksmucshluniversity-of-gavle
“…Concerning neoadjuvant chemotherapy, most trials administered three cycles [ 5 8 ]. Recently, Steger et al [ 16 ] compared two different neoadjuvant protocols in a single center retrospective study and concluded that the more aggressive protocol showed a better downstaging effect but survival difference did not reach significance. A two cycle strategy has been evaluated by a French group comparing mitomycin/ ifosfamid/ cisplatin with surgery alone [ 2 ].…”
Section: Discussionmentioning